Application of mTORC1 Inhibitors for Tissue-Agnostic Management of Standard-Therapy-Refractory Solid Tumors

SIMPLE SUMMARY: Hyperactivation of the mTOR pathway is a common occurrence in malignancies. This study investigated the clinical benefit of the tissue-agnostic application of mTOR inhibitors for the therapeutic management of a pan-cancer cohort of patients with mTOR pathway aberrations. Seventy-one...

Descripción completa

Detalles Bibliográficos
Autores principales: Taghizadeh, Hossein, Maj-Hes, Agnieszka, Prager, Gerald W., Müllauer, Leonhard, Mader, Robert M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032789/
https://www.ncbi.nlm.nih.gov/pubmed/35454843
http://dx.doi.org/10.3390/cancers14081936

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032789/
https://www.ncbi.nlm.nih.gov/pubmed/35454843
http://dx.doi.org/10.3390/cancers14081936

Ejemplares similares